GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinovac Biotech Ltd (FRA:SVQ) » Definitions » EV-to-FCF

Sinovac Biotech (FRA:SVQ) EV-to-FCF : 169.06 (As of May. 22, 2024)


View and export this data going back to . Start your Free Trial

What is Sinovac Biotech EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sinovac Biotech's Enterprise Value is €-6,598.2 Mil. Sinovac Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-39.0 Mil. Therefore, Sinovac Biotech's EV-to-FCF for today is 169.06.

The historical rank and industry rank for Sinovac Biotech's EV-to-FCF or its related term are showing as below:

FRA:SVQ' s EV-to-FCF Range Over the Past 10 Years
Min: -342.86   Med: 0.2   Max: 856.86
Current: 171.51

During the past 13 years, the highest EV-to-FCF of Sinovac Biotech was 856.86. The lowest was -342.86. And the median was 0.20.

FRA:SVQ's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 9.49 vs FRA:SVQ: 171.51

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-22), Sinovac Biotech's stock price is €5.58. Sinovac Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.971. Therefore, Sinovac Biotech's PE Ratio for today is At Loss.


Sinovac Biotech EV-to-FCF Historical Data

The historical data trend for Sinovac Biotech's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinovac Biotech EV-to-FCF Chart

Sinovac Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.12 -0.07 -0.55 5.79 167.10

Sinovac Biotech Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.55 - 5.79 - 167.10

Competitive Comparison of Sinovac Biotech's EV-to-FCF

For the Biotechnology subindustry, Sinovac Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinovac Biotech's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sinovac Biotech's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Sinovac Biotech's EV-to-FCF falls into.



Sinovac Biotech EV-to-FCF Calculation

Sinovac Biotech's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-6598.221/-39.028
=169.06

Sinovac Biotech's current Enterprise Value is €-6,598.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sinovac Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-39.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinovac Biotech  (FRA:SVQ) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Sinovac Biotech's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=5.58/-0.971
=At Loss

Sinovac Biotech's share price for today is €5.58.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sinovac Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.971.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Sinovac Biotech EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Sinovac Biotech's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinovac Biotech (FRA:SVQ) Business Description

Traded in Other Exchanges
N/A
Address
No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085
Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.

Sinovac Biotech (FRA:SVQ) Headlines

No Headlines